提供学术论文选刊润色服务
医学
医学
Paper Review Records
全部论文审稿周期
13 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
169
天
Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR -altered non-small-cell lung cancer
作者Natasha B. Leighl; Antonio Passaro; Hiroaki Akamatsu; Alexander I. Spira; Danny Nguyen; Angel Qin; Julia Schuchard; Mohamed Gamil; Mahadi Baig; Mariam Alexander
作者单位1. aPrincess Margaret Cancer Centre, Toronto, ON, Canada; 2. bDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; 3. cInternal Medicine III, Wakayama Medical University, Wakayama, Japan; 4. dVirginia Cancer Specialists, Fairfax, VA, USA; 5. eCity of Hope National Medical Center, Duarte, CA, USA; 6. fUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; 7. gJohnson & Johnson, Horsham, PA, USA; 8. hJohnson & Johnson, Spring House, PA, USA; 9. iJohnson & Johnson, Raritan, NJ, USA; 10. jHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
62
天
Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary
作者Leo Mascarenhas; Christopher Ollis; Yuvraj Singh; Linet Menachery; Domnita-Ileana Burcoveanu; Esther De La Cuesta; Cornelis M van Tilburg; Theodore W Laetsch
作者单位1. aGuerin Children’s and Cedars-Sinai Cancer, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA; 2. bPatient author; 3. cValley Springs, CA, USA; 4. dCaregiver author, Gurugram, Haryana, India; 5. eCaregiver author, White Plains, NY, USA; 6. fBayer HealthCare Pharmaceuticals, Inc, Basel, Switzerland; 7. gBayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA; 8. hHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; 9. iClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 10. jHeidelberg University, Heidelberg Faculty of Medicine, Department of Pediatric Oncology, Hematology, Immunology, and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; 11. kNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; 12. lChildren’s Hospital of Philadelphia / University of Pennsylvania, Philadelphia, PA, USA
163
天
Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors
作者Menghua Xia; Weifu Lv; Wei Zhao; Liqin Bi; Xueran Guo; Mengxia Zhang; Liangping Shi
作者单位1. The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China
183
天
Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences
作者Matthew Quaife; Cecilia Jimenez-Moreno; Blanca Gros Otero; Aisha Asra; Niodita Gupta-Werner; Katharine S. Gries; Marie-Kristin Leisten; Kathryn Matt; Robin Carson; Robyn Dennis; Jianming He; Bennett Levitan; Sacheeta Bathija
作者单位1. Evidera; 2. Johnson & Johnson
196
天
Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study
作者Shan Xu; Hao Yang; Nan Hu
作者单位1. The Third Affiliated Hospital of Nanjing Medical University; 2. The Third Affiliated Hospital of Soochow University
239
天
A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing
作者İmdat Eroğlu; Sıla Soylu Koçoğlu; Eron Merovci; Gözde Savaş; Fatih Gürler; Osman Sutcuoglu; Ugur Coskun; Aytug Uner; Murat Ucar; Burak Karaarslan; Ahmet Özet; Nuriye Özdemir; Ozan Yazıcı
作者单位1. Gazi University School of Medicine
125
天
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10
作者Hope S. Rugo; Peter Schmid; Javier Cortes; Toshimi Takano; Peter A. Fasching; Yeon Hee Park; Giampaolo Bianchini; Sandra Ximena Franco; Cynthia Villarreal-Garza; Olivier Tredan; Yongmei Yin; Romualdo Barroso-Sousa; Xuan Peng; Usha Malhotra; Karen Lisa Smith; Aditya Bardia
作者单位1. City of Hope Comprehensive Cancer Center; 2. Queen Mary University of London; 3. Quiron Group; 4. Cancer Institute Hospital of Japanese Foundation for Cancer Research; 5. University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg; 6. Sungkyunkwan University School of Medicine; 7. IRCCS Ospedale; 8. Vita-Salute San Raffaele University; 9. Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo; 10. Breast Cancer Center Hospital Zambrano Hellion TecSalud; 11. Centre Léon Bérard and Cancer Research Center of Lyon; 12. The First Affiliated Hospital of Nanjing Medical University; 13. Brasilia Hospital; 14. Inc; 15. University of California Los Angeles, Jonsson Comprehensive Cancer Center
83
天
Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience
作者Riddhi A. Babel; Stephen V. Liu; Tao Fan; Mayur M. Amonkar; Vamsidhar Velcheti
作者单位1. Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA; 2. Georgetown University; 3. Mayo Clinic
101
天
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States
作者Jennifer R. Brown; Talha Munir; Andrew H. Lipsky; Swetha Challagulla; David Campbell; Keri Yang; Qianhong Fu; Wassim Aldairy; Rhys Williams; Constantine S. Tam
作者单位1. Dana-Farber Cancer Institute and Harvard Medical School; 2. Leeds Teaching Hospitals NHS Trust; 3. Columbia University Medical Center; 4. BeOne Medicines Ltd., San Carlos, CA, USA; 5. Curta Inc., Seattle, WA, USA; 6. Alfred Hospital and Monash University
226
天
Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries
作者Harshali Patel; Lynn Huynh; Patrick Squires; Jennifer Prescott; Katherine Ryland; Maryaline Catillon; Tracy Guo; Kelvin Tamakloe; Steven Liu; Mei Sheng Duh; Monika Raut; Craig A. Portell
作者单位1. Merck & Co., Inc; 2. Analysis Group, Inc; 3. University of Virginia School of Medicine
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿96.4 天
中位数77 天